Wednesday, July 8, 2026

Drug profile · INN

gabapentin enacarbil

gabapentin enacarbil (HORIZANT) is a voltage-gated calcium channel modulator. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — gabapentin enacarbil
US status
approved
Class
Route
ORAL
Patents
0
Programs
0
Data quality
0.84

Quick answer

gabapentin enacarbil (HORIZANT) is a voltage-gated calcium channel modulator. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN gabapentin enacarbil
Brand HORIZANT
Mechanism Voltage-gated calcium channel modulator
Target Voltage-gated calcium channel
Route ORAL
Formulation TABLET, EXTENDED RELEASE

Mechanism of action

Voltage-gated calcium channel modulator

Primary target: Voltage-gated calcium channel

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. gabapentin Voltage-gated calcium channel modulator
  2. pregabalin Nervous system (N02)
  3. bepridil hydrochloride Voltage-gated calcium channel blocker
  4. gabapentin encarbil Voltage-gated calcium channel modulator

Frequently asked questions

What is gabapentin enacarbil?

gabapentin enacarbil (HORIZANT) is a voltage-gated calcium channel modulator. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for gabapentin enacarbil?

HORIZANT is a marketed brand name for gabapentin enacarbil. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of gabapentin enacarbil?

gabapentin enacarbil has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.